WO2001027126A1 - Process for the preparation of phosphorothioate triesters and oligonucleotides - Google Patents

Process for the preparation of phosphorothioate triesters and oligonucleotides

Info

Publication number
WO2001027126A1
WO2001027126A1 PCT/GB2000/003912 GB0003912W WO0127126A1 WO 2001027126 A1 WO2001027126 A1 WO 2001027126A1 GB 0003912 W GB0003912 W GB 0003912W WO 0127126 A1 WO0127126 A1 WO 0127126A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
process according
phosphonate
phosphorothioate
alkyl
Prior art date
Application number
PCT/GB2000/003912
Other languages
French (fr)
Inventor
Mark Edward Douglas
Kevin Gerard Scott
David John Moody
Ben James Mellor
Original Assignee
Avecia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avecia Limited filed Critical Avecia Limited
Priority to AU78035/00A priority Critical patent/AU7803500A/en
Priority to EP00968075A priority patent/EP1224193A1/en
Priority to JP2001530344A priority patent/JP2003517467A/en
Priority to CA002386867A priority patent/CA2386867A1/en
Publication of WO2001027126A1 publication Critical patent/WO2001027126A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Definitions

  • the present invention concerns a method for the synthesis of phosphorothioate tnesters, and particularly ohgonucleotides
  • a process for the synthesis of a phosphorothioate t ⁇ ester comprising the reaction, in the presence of a coupling agent, of an H-phosphonate with a substrate comprising a free hydroxy group and bonded to a solid support, thereby forming a supported H-phosphonate diester, and subjecting the H- phosphonate diester to sulphur transfer with a sulphur transfer agent thereby forming a phosphorothioate tnester
  • a plurality of coupling and sulphur transfer steps are carried out, with a sulphur transfer step being carried out after each coupling step
  • the H-phosphonate employed in the process of the present invention is often an
  • nucleosides are 2'- deoxy bonucleosides and nbonucleosides
  • preferred ohgonucleotides are o godeoxyribonucleotides and ohgoribonucleotides 2'-deoxyr ⁇ bonucleos ⁇ des and ohgodeoxyribonucleotides may comprise 2'-C-alkyl and 2'-C-alkenyl substituents
  • the H-phosphonate building block is a protected deoxynbonucleoside, nbonucleoside, ohgodeoxyribonucleotide or ohgoribonucleotide derivative comprising a 3' H-phosphonate function
  • the 5' hydroxy function is advantageously protected by a suitable protecting group
  • suitable protecting groups include acid labile protecting groups, particularly trityl and substituted trityl groups such as dimethoxyt ⁇ tyl and 9-phenylxanthen-9-yl groups, and base labile-protecting groups such as FMOC
  • Further protecting groups that may be employed include silyl ether groups
  • the 3' hydroxy function is advantageously protected by a suitable protecting group Suitable protecting groups include those disclosed above for the protection of the 5' hydroxy functions of 3' H-phosphonate building blocks and acyl, such as levulinoyi and substituted levuhnoyl, groups
  • the 2'-hydroxy function is advantageously protected by a suitable protecting group, for example an acid-labile acetal protecting group, particularly 1-(2- fluorophenyl)-4-methoxyp ⁇ per ⁇ d ⁇ ne-4-yl (Fpmp), and alkyl and aryl silyl protecting groups such as t-butyldiphenyl silyl groups, commonly tnalkylsilyl groups, often t ⁇ (C 1 4 -alkyl)s ⁇ lyl groups such as a tertiary butyl dimethylsilyl group
  • the ribonucleoside or oligonbonucleotide may be a 2'-O-alkyl, 2'-O-alkoxyalkyl or 2'-O-alkenyl derivative, commonly a C 1 4 alkyl, C 4 alkoxy ⁇ 4 alkyl or alkeny
  • the substrate comprising a free hydroxy group employed in the process of the present invention is commonly a protected nucleoside or ohgonucleotide comprising a free hydroxy group, preferably a free 3' or 5' hydroxy group, and particularly preferably a 5' hydroxy group
  • preferred nucleosides are deoxy ⁇ bonucleosides and ⁇ bonucleosides and preferred ohgonucleotides are ohgodeoxyribonucleotides and ohgo ⁇ bonucleotides
  • the substrate comprising a free hydroxy group is a deoxynbonucleoside, ribonucleoside, ohgodeoxyribonucleotide or oligonbonucleotide derivative comprising a free 5'-hydroxy group
  • the substrate comprising a free hydroxy group is preferably bonded to the solid support via the 3'-hydroxy function
  • the substrate comprising a free hydroxy group is a deoxynbonucleoside, ribonucleoside, ohgodeoxyribonucleotide or oligonbonucleotide derivative comprising a free 3'-hydroxy group
  • the substrate comprising a free hydroxy group is preferably bonded to the solid support via the 5'-hydroxy function
  • the 2'-hydroxy function is advantageously protected by a suitable protecting group, such as an acetal, particularly 1-(2-fluorophenyl)-4-methoxyp ⁇ per ⁇ d ⁇ ne-4- yl (Fpmp), and t ⁇ alkylsilyl groups, often t ⁇ (C 1 4 -alkyl)s ⁇ lyl groups such as a tertiary butyl dimethyl silyl group
  • the ribonucleoside or oligonbonucleotide may be
  • substrates comprising a free hydroxy group that may be employed in the process according to the present invention are saccha ⁇ des, especially abasic nucleosides such as ⁇ bose and deoxy ⁇ bose, and non-saccha ⁇ de polyols, especially alkyl polyols, and preferably diols or t ⁇ ols
  • alkyl diols include ethane-1 ,2-d ⁇ ol, and low molecular weight poly(ethylene glycols), such as those having a molecular weight of up to 400
  • alkyl t ⁇ ols include glycerol and butane t ⁇ ols
  • suitable protecting groups such as those disclosed hereinabove for the protection at the 5' or 2' positions of nbonucleosides, or being employed to bond the substrate to the solid support
  • more than one free hydroxy group may be present if it is desired to perform
  • bases present in nucleosides/nucleotides employed in present invention are also preferably protected where necessary by suitable protecting groups
  • protecting groups employed are those known in the art for protecting such bases
  • adenine (A) and/or cytosine (C) can be protected by benzoyl, including substituted benzoyl, for example alkyl- or alkoxy-, often C 1 4 alkyl- or C 1 4 alkoxy-, benzoyl, pivaloyl, and amidine, particularly dialkylaminomethylene, preferably d ⁇ (C 1 4 -alkyl) aminomethylene such as dimethyl or dibutyl aminomethylene
  • Guanine (G) may be protected by a phenyl group, including substituted phenyl, for example 2,5-d ⁇ chlorophenyl and also by an isobutyryl group G may also be protected by diphenylcarbamoyl and glyoxal type protecting groups thymine (T)
  • the phosphorothioate tnester produced is a protected nucleoside or ohgonucleotide having protected hydroxy groups
  • one of these protecting groups may be removed after carrying out the process of the first invention Commonly, the protecting group removed is that on the 5'-hydroxy function
  • the ohgonucleotide thus formed may then proceed through further stepwise or block coupling and sulphur transfers according to the process of the present invention in the synthesis of a desired ohgonucleotide sequence
  • the method may then proceed with steps to remove the protecting groups from the intemucleotide linkages, the 3' and the 5'- hydroxy groups and from the bases, and to cleave the product from the solid support
  • the process according to the present invention may comprise a capping step, where hydroxy groups which are unreacted after a given coupling are capped to prevent further reaction in later couplings
  • Capping agents which may be employed are those known in the art for such a step, and include for example acylating agents such as acetic anhydride, (preferably in the presence of a nucleophihc acylation catalyst such as 4-(N,N- d ⁇ methyl)am ⁇ nopy ⁇ d ⁇ ne) and lower, eg up to C 4 , alkyl H-phosphonates, such as ethyl H- phosphonate, and 2-cyanoethyl H-phosphonate
  • the invention provides a method comprising the coupling of a 5'-0-(4,4'-d ⁇ methoxytr ⁇ tyl)-2'-deoxy ⁇ bonucleos ⁇ de Z'-H- phosphonate or a protected ohgodeoxyribonucleotide 3'-H-phosphonate and a substrate supported on a solid support with a free hydroxy function, most commonly a 2'- deoxy ⁇ bonucleoside or ohgodeoxyribonucleotide, in the presence of a suitable coupling agent and subsequent sulphur transfer in the presence of a suitable sulphur-transfer agent
  • any suitable coupling agents and sulphur- transfer agents available in the prior art may be used
  • suitable coupling agents include alkyl and aryl acid chlorides, alkane and arene sulphonyl chlorides, alkyl and aryl chloroformates, alkyl and aryl chlorosulphites and alkyl and aryl phosphorochlondates, and carbodiimides
  • suitable alkyl acid chlorides which may be employed include up to C 12 alkyl acid chlorides, including adamantyl carbonyl chloride, and especially C 2 to C 7 alkanoyl chlorides, particularly pivaloyl chloride
  • aryl acid chlorides which may be employed include substituted and unsubstituted benzoyl chlorides, such as C, 4 alkoxy, halo, particularly fluoro, chloro and bromo, and C 1 4 alkyl, substituted benzoyl chlorides When substituted, from 1 to 3 substituents are often present, particularly in the case of alkyl and halo substituents
  • alkanesulphonyl chlorides which may be employed include C 2 to C 7 alkanesulphonyl chlorides
  • arenesulphonyl chlorides which may be employed include substituted and unsubstituted benzenesulphonyl chlorides, such as C-, 4 alkoxy, halo, particularly fluoro, chloro and bromo, and C-, 4 alkyl, substituted benzenesulphonyl chlorides When substituted, from 1 to 3 substituents are often present, particularly in the case of alkyl and halo substituents
  • alkyl chloroformates examples include C 2 to C 7 alkyl chloroformates
  • aryl chloroformates which may be employed include substituted and unsubstituted phenyl chloroformates, such as C, 4 alkoxy, halo, particularly fluoro, chloro and bromo, and C 1 4 alkyl, substituted phenyl chloroformates When substituted, from 1 to 3 substituents are often present, particularly in the case of alkyl and halo substituents
  • suitable alkyl chlorosulphites which may be employed include C 2 to
  • C 7 alkyl chlorosulphites examples include substituted and unsubstituted phenyl chlorosulphites, such as C 1 4 alkoxy, halo, particularly fluoro, chloro and bromo, and C 1 4 alkyl, substituted phenyl chlorosulphites When substituted, from 1 to 3 substituents are often present, particularly in the case of alkyl and halo substituents
  • alkyl phosphorochlo ⁇ dates which may be employed include d ⁇ (C, to C 6 alkyl) phosphorochlo ⁇ dates
  • aryl phosphorochlo ⁇ dates which may be employed include substituted and unsubstituted diphenyl phosphorochlo ⁇ dates, such as C, 4 alkoxy, halo, particularly fluoro, chloro and bromo, and C, 4 alkyl, substituted diphenyl phosphorochlo ⁇ dates When substituted, from 1 to 5 substituents on each phenyl group may be present, particularly in the case of alkyl and halo substituents
  • alkyl carbodiimides especially (C, to C 6 alkyl) carbodiimides, such as 1 ,3 dicyclohexyl carbodiimide, 1 ,3 dnsopropyl carbodiimide, 1-tert -butyl-3-ethyl carbodnmide and 1-(3- d ⁇ methylam ⁇ nopropyl)-3-ethyl carbodiimide
  • alkyl carbodiimides especially (C, to C 6 alkyl) carbodiimides, such as 1 ,3 dicyclohexyl carbodiimide, 1 ,3 dnsopropyl carbodiimide, 1-tert -butyl-3-ethyl carbodnmide and 1-(3- d ⁇ methylam ⁇ nopropyl)-3-ethyl carbodiimide
  • One or more of the alkyl groups may be substituted, for example by an alkyl ammo moiety
  • Preferred coupling agents are diaryl phosphorochloridat.es, particularly those having the formula (ArO) 2 POCI wherein Ar is preferably phenyl, 2-chlorophenyl, 2,4,6- t ⁇ chlorophenyl or 2,4,6-tr ⁇ bromophenyl
  • the sulphur transfer agents employed in the process of the present invention introduce a protected thio moiety into the linkage, thereby forming a phosphorothioate tnester
  • the phosphorthioate t ⁇ esters are commonly subsequently converted to phosphodiester or phosphorothioate diesters, and the sulphur transfer agent can be selected accordingly
  • the nature of the sulphur-transfer agent will depend on whether an ohgonucleotide, a phosphorothioate analogue or a mixed ohgonucleotide/ohgonucleotide phosphorothioate is required
  • Sulphur transfer agents employed in the process of the present invention often have the general chemical formula
  • L represents a leaving group
  • D represents an aryl group, a methyl or a substituted alkyl group or an alkenyl group
  • the leaving group is selected so as to comprise a nitrogen-sulphur bond
  • suitable leaving groups include morphohnes such as morphohne-3,5-d ⁇ one, imides such as phthahmides, succinimides and maleimides, indazoles, particularly indazoles with electron-withdrawing substituents such as 4-n ⁇ tro ⁇ ndazoles, and t ⁇ azoles
  • the sulphur transfer agent is commonly selected such that the moiety D represents an aryl group, such as a phenyl or naphthyl group
  • suitable aryl groups include substituted and unsubstituted phenyl groups, particularly halophenyl and alkylphenyl groups, especially 4-halophenyl and 4-alkylphenyl, commonly 4-(C ⁇ 4 alkyl)phenyl groups, most preferably 4-chlorophenyl and p-tolyl groups
  • An example of a suitable class of standard phosphodiester-directing sulphur-transfer agent is an N- (arylsulphanyl)phthahm ⁇ de (succinimide or other imide may also be used)
  • the moiety D commonly represents a methyl, substituted alkyl or alkenyl group
  • suitable substituted alkyl groups include substituted methyl groups, particularly benzyl and substituted benzyl groups, such as alkyl-, commonly C, 4 alkyl- and halo-, commonly chloro-, substituted benzyl groups, and substituted ethyl groups, especially ethyl groups substituted at the 2-pos ⁇ t ⁇ on with an electron-withdrawing substituent such as 2-(4- n ⁇ trophenyl)ethyl and 2-cyanoethyl groups
  • suitable alkenyl groups are ally], propargyl and crotyl
  • Examples of a suitable class of phosphorothioate-directing sulphur- transfer agents are, for example, (2-cyanoethyl)sulphanyl derivatives such as 4-[(2- cyanoethyl)-sulphanyl]
  • a suitable temperature for carrying out the coupling reaction and sulphur transfer is in the range of from approximately -55°C to about 40°C, such as from 0 to 30°C, and preferably about room temperature (commonly in the range of from 10 to 25°C, for example approximately 20°C)
  • Preferred nucleoside or nucleotide H-phosphonates employed in the process of the present invention have the general chemical formula wherein each B independently is an organic base, each Q independently is H, CH 2 R' or OR' wherein R' is alkyl, substituted alkyl, alkenyl or a protecting group, each R independently is an aryl, methyl, substituted alkyl or alkenyl group,
  • W is H, a protecting group or an H-phosphonate group of formula
  • M + is a monovalent cation
  • each X independently represent O or S
  • each Y independently represents O or S
  • Z is H, a protecting group or an H-phosphonate group of formula
  • M + is a monovalent cation
  • n is zero or a positive integer
  • W or Z is an H-phosphonate group, commonly only Z being an H-phosphonate group
  • the protecting group may be one of those disclosed above for protecting the 3' or 5' positions respectively
  • the protecting group is preferably a trityl group, particularly a dimethoxyt ⁇ tyl group
  • the protecting group is preferably a trityl group, particularly a dimethoxytntyl group, or an acyl group, preferably a levuhnoyl group
  • Organic bases which may be represented by B include nucleobases, such as natural and unnatural nucleobases, and especially pu ⁇ nes, such as hypoxanthine, and particularly A and G, and pynmidines, particularly T, C and U
  • the bases may be protected, with A, G and C preferably being protected Suitable protecting groups include those described hereinabove for the protection of bases
  • the alkenyl group is often a C, 4 alkenyl group, especially allyl, propargyl or crotyl group
  • the alkyl is preferably a C 1 4 alkyl group
  • the substituted alkyl group includes alkoxyalkyl groups, especially C-, 4 alkyoxy ⁇ 4 alkyl groups such as methoxyethyl groups
  • the protecting group is commonly an acid-labile acetal protecting group, particularly 1-(2- fluorophenyl)-4-methoxyp ⁇ per ⁇ d ⁇ ne-4-yl (Fpmp) or a t ⁇ alkylsilyl groups, often a t ⁇ 4 - alkyl)s ⁇ lyl group such as a tertiary butyl dimethylsilyl group
  • X represents O
  • Y represents S and each
  • H-phosphonates wherein n represents 1 , 2 or 3 can be employed when it is desired to add small blocks of nucleotide, with correspondingly larger values of n, for example 4, 5, or 6, being employed if larger blocks of ohgonucleotide are desired to be coupled
  • H-phosphonates, coupling agents and sulphur transfer agents can employed as a solution, although the coupling agent or sulphur transfer agent may employed as a neat liquid or solid as appropriate
  • Organic solvents which can be employed include haloalkanes, particularly dichloromethane, esters, particularly alkyl esters such as ethyl acetate, and methyl or ethyl propionate, nitriles, such as acetonit ⁇ le, amides, such as dimethylformamide and N-methylpyrolhdinone, and basic, nucleophihc solvents such as py ⁇ dine Preferred solvents are py ⁇ dine, dichloromethane, dimethylformamide, N- methylpyrolhdinone and mixtures thereof
  • Protecting groups can be removed using methods known in the art for the particular protecting group and function
  • transient protecting groups particularly gamma keto acids such as levuhnoyl-type protecting groups
  • hydrazine for example, buffered hydrazine, such as the treatment with hydrazine under very mild conditions disclosed by van Boom J H , Burgers, P M J Tetrahedron Lett , 1976, 4875-4878
  • the resulting partially-protected ohgonucleotides with free 3'-hydroxy functions may then be converted into the corresponding H- phosphonates which are intermediates which can be employed for the block synthesis of ohgonucleotides and their phosphorothioate analogues
  • a cyanoethyl group can be removed by treatment with anhydrous, strongly basic amine such as DABCO, 1 ,5-d ⁇ azab ⁇ cylo[4 3 0]non-5-ene (DBN), 1 ,8-d ⁇ azab ⁇ cyclo[5 4 0]undec-7-ene (DBU) or tnethylamine
  • Phenyl and substituted phenyl groups on the phosphorothioate intemucleotide linkages and on the base residues can be removed by oximate treatment, for example with the conjugate base of an aldoxime, preferably that of E-2-n ⁇ trobenzaldox ⁇ me or py ⁇ d ⁇ ne-2-carboxaldox ⁇ me (Reese et al, Nucleic Acids Res 1981 ) Kamimura, T et al in
  • Trityl groups present can be removed by treatment with acid
  • acid With regard to the overall unblocking strategy in ohgonucleotide synthesis, another important consideration of the present invention, is that the removal of trityl, often a 5'-term ⁇ nal DMTr, protecting group ('det ⁇ tylation') should proceed without concomitant depu ⁇ nation, especially of any 6- ⁇ /-acyl-2'-deoxyadenos ⁇ ne residues
  • Silyl protecting groups may be removed by fluoride treatment, for example with a solution of an ammonium fluoride, for example a solution of t ⁇ alkylamine t ⁇ hydrogen fluoride or a solution of a tetraalkyl ammonium fluoride salt such as tetrabutyl ammonium fluoride
  • Fpmp protecting groups may be removed by acidic hydrolysis under mild conditions
  • the substrate is commonly bound to the solid support via a cleavable linker
  • linkers that may be employed include those well known in the art for the solid phase synthesis of ohgonucleotides, such as urethane, oxalyl, succinyl, and amino- de ⁇ ved linkers
  • the substrate is attached to the support by a process comprising either a) reacting a 5'-protected nuceloside having a free 3'-hydroxy group with a linker, preferably succinic anhydride, to form a linker-de ⁇ vatised nucleoside, and b) reacting the linker-de ⁇ vatised nucleoside with an amine-functionahsed poly(acrylam ⁇ de) support in the presence of a coupling agent used for amide bond formation and optionally a catalyst, such as a base, for example
  • Coupling agents used for amide bond formation that can be employed in the process for attaching the substrate to an amine-functionahsed poly(acrylam ⁇ de) support include those known in the art of peptide synthesis, see for example those coupling reagents disclosed by Wel ngs, D A , Atherton, E , in Methods in Enzymology, Publ , Academic Press, New York (1997) incorporated herein by reference, such as those comprising carbodiimides, especially dialkyl carbodiimides such as N,N'- diisopropylcarbodnmide (DIC) and reagents that form active esters particularly benzot ⁇ azole active esters in situ, such as 2-(1 H-benzot ⁇ azole-1-yl)-1 , 1 ,3,3- tetramethyluronium tetrafluoroborate (TBTU) or benzot ⁇ azole-1-yloxy-t ⁇ s-
  • DIC diisopropylcarbodnmide
  • An organic solvent such as N,N-d ⁇ methylformam ⁇ de (DMF) or N- methylpyrrohdinone (NMP) is suitably employed for attaching the substrate to an amine- functiona sed poly(acrylam ⁇ de) support
  • DMF N,N-d ⁇ methylformam ⁇ de
  • NMP N- methylpyrrohdinone
  • the process for the synthesis of phosphorothioate t ⁇ esters according to the present invention can be carried out by stirring a slurry of the substrate bonded to the solid in a solution of the H-phosphonate and coupling agent or sulphur-transfer agent
  • the solid support can be packed into a column, and solutions of H- phosphonate and coupling agent, followed by sulphur transfer agent can be passed sequentially through the column
  • the process according to the present invention is preferably employed to produce ohgonucleotides typically comprising 3 or more bases
  • the upper limit will depend on the length of the ohgonucleotide it is desired to prepare Often, ohgonucleotides produced by the process of the present invention comprise up to 40 bases, commonly up to 30 bases and preferably from 5 to 25, such as from 8 to 20, bases
  • the coupling and sulphur transfer steps of the process of the present invention are repeated sufficient times to produce the desired length and sequence
  • the product may be cleaved from the solid support, preferably following deprotection of the product
  • the desired product is an ohgonucleotide
  • the product will be a phosphate diester, phosphorothioate diester or chimera comprising both phosphate diester and phosphorothioate diester moieties
  • Cleavage methods employed are those known in the art for the given solid support
  • cleavage methods appropriate for the linker are employed following cleavage, the product can be purified using techniques known in the art, such as one or more of ion-exchange chromatography, reverse phase chromatography, and precipitation from an appropriate solvent Further processing of the product by for example ultrafiltration may also be employed
  • the invention will now be illustrated without limitation by the following examples
  • DMT C z 4- ⁇ /-benzoyl-5'-0-(4,4'-d ⁇ methoxytr ⁇ tyl)-2'-deoxycyt ⁇ d ⁇ ne (DMT C z ) supported via a succinimide linker at the 3'-pos ⁇ t ⁇ on to a polystyrene support (commercially available under the trade name Pharmacia Primer Support 30HL, loading 84 umol/g, 2g) was poured into a sintered vessel, wetted with 100ml of CH 2 CH 2 , and aerated with house nitrogen The solvent was removed Following this wash procedure, the supported DMT C bz was treated as follows i) with 100ml of 3% v/v dichloroacetic acid in dichloromethane (DCA/DCM) - Wait for 60 seconds, remove DCA/DCM n) with 100ml of CH 2 CH 2 - Wait for 60 seconds, remove CH 2 CH 2 in) with 100ml of 3% DCA/DCM - Wait for
  • a 5'-DMT protected nucleotide 3'-H-phosphonate having the base sequence 5'- DMT-ACAC, with each intemucleotide being protected by a beta-cyanoethylthio moiety (5'-DMT-ACAC-3'-H phosphonate) was prepared from the corresponding tetrame ⁇ c ohgonucleotide comprising a free 3'-hydroxy group (5'-DMT-ACAC-3'-OH) as follows Ammonium toluyl-H-phosphonate was dissolved in 50ml methanol and 5ml t ⁇ ethylamine This mixture is evaporated to form a gum, and the gum redissolved in 100ml pyndine, together with 12 3g 5'-DMT-ACAC-3'-OH, and the pyndine evaporated The residue was then redissolved in 50ml pyndine The pyndine solution is cooled to -30°C and pivaloyl chloride (2 2
  • the cyanoethyl groups can be removed by treatment with anhydrous 1 ,8- d ⁇ azab ⁇ cyclo[5,4,0]undec-7-ene to yield phosphorothioate linkages, and the phosphorothioate ohgonucleotide could be cleaved from the support by treatment with concentrated aqueous ammonia containing 10% vol mercaptoethanol
  • a poly(acrylam ⁇ de) resin produced by copolyme ⁇ sation of acryloyl-sarcosine methyl ester, N,N-d ⁇ methylacrylam ⁇ de and bis-acryloylethylenediamine (PDMA resin, 69g) was treated with ethylene diamine (700ml) in a 2L round bottomed flask which was sealed and allowed to stand at room temperature overnight The slurry was then transferred to a sinter funnel and washed with DMF (12x 700ml) This produced DMF washings containing no trace of amine The resin was then washed with DMF containing an increasing gradient of DCM (2 5L, 0-100% DCM) then an increasing gradient of ether in DCM (900ml, 0-100% ether) The resin was then dried overnight in a stream of nitrogen at 40°C The resin produced had an ammo functionahsation of 973 micromoles per gram ("Ammo-PDMA resin”)
  • a 5'-DMT-deoxycyt ⁇ d ⁇ ne dimer (protected on the mternucleoside phsophorus by a ⁇ -cyanoethyl group) was also attached to the resin at a similar loading using identical conditions to above
  • the loaded resin was prepared for coupling by having the DMT group removed as follows DMT-C bz -PDMA resin is poured into a sintered funnel (7cm, porosity 3) and a positive pressure of nitrogen is applied A 3% solution of DCA in DCM (15ml/g resin) is then added to the resin and left to bubble gently for 5 minutes This was repeated (twice, quantities same as above) All of the orange colour was removed from the resin at this point indicating that det ⁇ tylation is complete Residual acid was removed by washing with

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)

Abstract

A process for the synthesis of a phosphorothioate triester is provided. The process comprises the reaction, in the presence of a coupling agent, of an H-phosphonate with a substrate comprising a free hydroxy group and bonded to a solid support, thereby forming a supported H-phosphonate diester, and subjecting the H-phosphonate diester to sulphur transfer with a sulphur transfer agent.

Description

PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS AND
OLIGONUCLEOTIDES
The present invention concerns a method for the synthesis of phosphorothioate tnesters, and particularly ohgonucleotides
In the past 15 years or so, enormous progress has been made in the development of the synthesis of oligodeoxyπbonucleotides (DNA sequences), oligoπbonucleotides (RNA sequences) and their analogues, see 'Methods in Molecular Biology, Vol 20, Protocol for Ohgonucleotides and Analogs', Agrawal, S Ed , Humana Press, Totowa, 1993 Much of the work has been carried out on a micromolar or even smaller scale, and automated solid phase synthesis involving monomeπc phosphoramidite building blocks Beaucage, S L , Caruthers, M H Tetrahedron Lett , 1981 , 22, 1859-1862 has proved to be the most convenient approach Indeed, high molecular weight DNA and relatively high molecular weight RNA sequences can now be prepared routinely with commercially available synthesisers These synthetic ohgonucleotides have met a number of crucial needs in biology and biotechnology
Following Zamecnik and Stephenson's seminal discovery that a synthetic ohgonucleotide could selectively inhibit gene expression in Rous sarcoma virus, (Zamecnik, P , Stephenson, M Proc Natl Acad Sci USA 1978, 75, 280-284), the idea that synthetic ohgonucleotides or their analogues might well find application in chemotherapy has attracted a great deal of attention both in academic and industrial laboratories For example, the possible use of ohgonucleotides and their phosphorothioate analogues in chemotherapy has been highlighted in the report of Gura,
T Science, 1995, 270, 575-577 The so-called antisense and antigene approaches to chemotherapy (Ohgonucleotides Antisense Inhibitors of Gene Expression, Cohen J S , Ed , Macmillan, Basingstoke 1989 Moser, H E , Dervan, P B Science 1987, 238, 645- 649), have profoundly affected the requirements for synthetic ohgonucleotides Whereas milligram quantities have generally sufficed for molecular biological purposes, gram to greater than 100 gram quantities are required for clinical trials Several ohgonucleotide analogues that are potential antisense drugs are now in advanced clinical trials If as seems likely in the very near future, one of these sequences becomes approved, say, for the treatment of AIDS or a form of cancer, kilogram or more probably multikilogram quantities of a specific sequence or sequences will be required
Three main methods, namely the phosphotriester (Reese, Tetrahedron, 1978) phosphoramidite (Beaucage, S L in Methods in Molecular Biology, Vol 20, Agrawal, S Ed , Humana Press, Totowa, 1993, pp 33-61) and H-phosphonate (Froehler, B C in Methods in Molecular Biology, Vol 20, Agrawal, S , Ed , Humana Press, Totowa, 1993, pp 63-80) approaches have proved to be effective for the chemical synthesis of ohgonucleotides While the phosphotriester approach has been used most widely for synthesis in solution, the phosphoramidite and H-phosphonate approaches have been used almost exclusively in solid phase synthesis The conventional H-phosphonate synthesis approach has been found to have a number of disadvantages First, the process involves the use of an intermediate chain comprising a plurality of reactive H- phosphonate internucleotide linkages The reactivity of these linkages can cause degradation, and hence lower yields and purities Additionally, the use of a single oxidation or sulphunsation step at the end of the assembly of the desired molecule means that the process cannot readily be employed for the controlled production of chimenc nucleotides Furthermore, when an oxidation step is employed, this is slow, and can cause concomitant degradation, and when a sulphunsation step is employed, not only are the reagents toxic, but the reaction is also slow Additionally, the most common sulphunsation reagent, the so-called "Beaucage Reagent", can introduce a significant, and unpredictable, proportion of oxygen, in place of the expected sulphur Attempts to improve the conventional H-phosphonate approach, for example that taught in EP-A-0 219 342 using acylating agents themselves have problems, for example the low coupling yields achieved with acylating agents
According to the present invention, there is provided a process for the synthesis of a phosphorothioate tπester comprising the reaction, in the presence of a coupling agent, of an H-phosphonate with a substrate comprising a free hydroxy group and bonded to a solid support, thereby forming a supported H-phosphonate diester, and subjecting the H- phosphonate diester to sulphur transfer with a sulphur transfer agent thereby forming a phosphorothioate tnester In many highly preferred embodiments, a plurality of coupling and sulphur transfer steps are carried out, with a sulphur transfer step being carried out after each coupling step The H-phosphonate employed in the process of the present invention is often an
H-phosphonate monoester, and advantageously a protected nucleoside or ohgonucleotide H-phosphonate, preferably comprising a 5' or a 3' H-phosphonate function, particularly preferably a 3' H-phosphonate function Preferred nucleosides are 2'- deoxy bonucleosides and nbonucleosides, preferred ohgonucleotides are o godeoxyribonucleotides and ohgoribonucleotides 2'-deoxyrιbonucleosιdes and ohgodeoxyribonucleotides may comprise 2'-C-alkyl and 2'-C-alkenyl substituents
When the H-phosphonate building block is a protected deoxynbonucleoside, nbonucleoside, ohgodeoxyribonucleotide or ohgoribonucleotide derivative comprising a 3' H-phosphonate function, the 5' hydroxy function is advantageously protected by a suitable protecting group Examples of such suitable protecting groups include acid labile protecting groups, particularly trityl and substituted trityl groups such as dimethoxytπtyl and 9-phenylxanthen-9-yl groups, and base labile-protecting groups such as FMOC Further protecting groups that may be employed include silyl ether groups
When the H-phosphonate building block is a protected deoxynbonucleoside ribonucleoside, ohgodeoxyribonucleotide or oligonbonucleotide derivative comprising a 5' H-phosphonate function, the 3' hydroxy function is advantageously protected by a suitable protecting group Suitable protecting groups include those disclosed above for the protection of the 5' hydroxy functions of 3' H-phosphonate building blocks and acyl, such as levulinoyi and substituted levuhnoyl, groups
When the H-phosphonate is a protected ribonucleoside or a protected oligonbonucleotide, the 2'-hydroxy function is advantageously protected by a suitable protecting group, for example an acid-labile acetal protecting group, particularly 1-(2- fluorophenyl)-4-methoxypιperιdιne-4-yl (Fpmp), and alkyl and aryl silyl protecting groups such as t-butyldiphenyl silyl groups, commonly tnalkylsilyl groups, often tπ(C1 4-alkyl)sιlyl groups such as a tertiary butyl dimethylsilyl group Alternatively, the ribonucleoside or oligonbonucleotide may be a 2'-O-alkyl, 2'-O-alkoxyalkyl or 2'-O-alkenyl derivative, commonly a C1 4 alkyl, C 4 alkoxy^ 4alkyl or alkenyl derivative, in which case, the 2' position does not need further protection Other H-phosphonates that may be employed in the process according to the present invention are derived from polyfunctional alcohols, especially alkyl alcohols, and preferably diols or tπols Examples of alkyl diols include ethane-1 ,2-dιol, and low molecular weight poly(ethylene glycols), such as those having a molecular weight of up to 400 Examples of alkyl tπols include glycerol and butane tnols Further polyfunctonal alcohols include sacchaπdes, especially abasic nucleosides, for example πbose and deoxyπbose Commonly, only a single H-phosphonate function will be present, the remaining hydroxy groups being protected by suitable protecting groups, such as those disclosed hereinabove for the protection at the 5' or 2' positions of πbonucleosides
The substrate comprising a free hydroxy group employed in the process of the present invention is commonly a protected nucleoside or ohgonucleotide comprising a free hydroxy group, preferably a free 3' or 5' hydroxy group, and particularly preferably a 5' hydroxy group
When the substrate comprising a free hydroxy group is a protected nucleoside or a protected ohgonucleotide, preferred nucleosides are deoxyπbonucleosides and πbonucleosides and preferred ohgonucleotides are ohgodeoxyribonucleotides and ohgoπbonucleotides
When the substrate comprising a free hydroxy group is a deoxynbonucleoside, ribonucleoside, ohgodeoxyribonucleotide or oligonbonucleotide derivative comprising a free 5'-hydroxy group, the substrate comprising a free hydroxy group is preferably bonded to the solid support via the 3'-hydroxy function
When the substrate comprising a free hydroxy group is a deoxynbonucleoside, ribonucleoside, ohgodeoxyribonucleotide or oligonbonucleotide derivative comprising a free 3'-hydroxy group, the substrate comprising a free hydroxy group is preferably bonded to the solid support via the 5'-hydroxy function When the substrate comprising a free hydroxy group is a ribonucleoside or an oligonbonucleotide, the 2'-hydroxy function is advantageously protected by a suitable protecting group, such as an acetal, particularly 1-(2-fluorophenyl)-4-methoxypιperιdιne-4- yl (Fpmp), and tπalkylsilyl groups, often tπ(C1 4-alkyl)sιlyl groups such as a tertiary butyl dimethyl silyl group Alternatively, the ribonucleoside or oligonbonucleotide may be a 2'- O-alkyl, 2'-O-alkoxyalkyl or 2-'O-alkenyl derivative, commonly a C, 4 alkyl, C, 4 alkoxy^ 4alkyl or alkenyl derivative, in which case, the 2' position does not need further protection
Other substrates comprising a free hydroxy group that may be employed in the process according to the present invention are sacchaπdes, especially abasic nucleosides such as πbose and deoxyπbose, and non-sacchaπde polyols, especially alkyl polyols, and preferably diols or tπols Examples of alkyl diols include ethane-1 ,2-dιol, and low molecular weight poly(ethylene glycols), such as those having a molecular weight of up to 400 Examples of alkyl tπols include glycerol and butane tπols Commonly, only a single free hydroxy group will be present, the remaining hydroxy groups being protected by suitable protecting groups, such as those disclosed hereinabove for the protection at the 5' or 2' positions of nbonucleosides, or being employed to bond the substrate to the solid support However, more than one free hydroxy group may be present if it is desired to perform identical couplings on more than one hydroxy group
In addition to the presence of hydroxy protecting groups, bases present in nucleosides/nucleotides employed in present invention are also preferably protected where necessary by suitable protecting groups Protecting groups employed are those known in the art for protecting such bases For example, adenine (A) and/or cytosine (C) can be protected by benzoyl, including substituted benzoyl, for example alkyl- or alkoxy-, often C1 4 alkyl- or C1 4alkoxy-, benzoyl, pivaloyl, and amidine, particularly dialkylaminomethylene, preferably dι(C1 4-alkyl) aminomethylene such as dimethyl or dibutyl aminomethylene Guanine (G) may be protected by a phenyl group, including substituted phenyl, for example 2,5-dιchlorophenyl and also by an isobutyryl group G may also be protected by diphenylcarbamoyl and glyoxal type protecting groups thymine (T) and uracil (U) generally do not require protection, but in certain embodiments may advantageously be protected, for example at O4 by a phenyl group, including substituted phenyl, for example 2,4-dιmethylphenyl or at N3 by a pivaloyloxymethyl, benzoyl, alkyl or alkoxy substituted benzoyl, such as ^ 4 alkyl- or C-, 4 alkoxybenzoyl
After the coupling and sulphur transfer steps, and when it is desired to carry out further coupling and sulphur transfer steps, it is often necessary to introduce a free hydroxyl group into the phosphorothioate tnester produced by the process of the present invention When the phosphorothioate tnester produced is a protected nucleoside or ohgonucleotide having protected hydroxy groups, one of these protecting groups may be removed after carrying out the process of the first invention Commonly, the protecting group removed is that on the 5'-hydroxy function After the protecting group has been removed, the ohgonucleotide thus formed may then proceed through further stepwise or block coupling and sulphur transfers according to the process of the present invention in the synthesis of a desired ohgonucleotide sequence The method may then proceed with steps to remove the protecting groups from the intemucleotide linkages, the 3' and the 5'- hydroxy groups and from the bases, and to cleave the product from the solid support
The process according to the present invention may comprise a capping step, where hydroxy groups which are unreacted after a given coupling are capped to prevent further reaction in later couplings Capping agents which may be employed are those known in the art for such a step, and include for example acylating agents such as acetic anhydride, (preferably in the presence of a nucleophihc acylation catalyst such as 4-(N,N- dιmethyl)amιnopyπdιne) and lower, eg up to C4, alkyl H-phosphonates, such as ethyl H- phosphonate, and 2-cyanoethyl H-phosphonate
In a particularly preferred embodiment, the invention provides a method comprising the coupling of a 5'-0-(4,4'-dιmethoxytrιtyl)-2'-deoxyπbonucleosιde Z'-H- phosphonate or a protected ohgodeoxyribonucleotide 3'-H-phosphonate and a substrate supported on a solid support with a free hydroxy function, most commonly a 2'- deoxyπbonucleoside or ohgodeoxyribonucleotide, in the presence of a suitable coupling agent and subsequent sulphur transfer in the presence of a suitable sulphur-transfer agent In the process of the present invention, any suitable coupling agents and sulphur- transfer agents available in the prior art may be used
Examples of suitable coupling agents include alkyl and aryl acid chlorides, alkane and arene sulphonyl chlorides, alkyl and aryl chloroformates, alkyl and aryl chlorosulphites and alkyl and aryl phosphorochlondates, and carbodiimides Examples of suitable alkyl acid chlorides which may be employed include up to C12 alkyl acid chlorides, including adamantyl carbonyl chloride, and especially C2 to C7 alkanoyl chlorides, particularly pivaloyl chloride Examples of aryl acid chlorides which may be employed include substituted and unsubstituted benzoyl chlorides, such as C, 4 alkoxy, halo, particularly fluoro, chloro and bromo, and C1 4 alkyl, substituted benzoyl chlorides When substituted, from 1 to 3 substituents are often present, particularly in the case of alkyl and halo substituents
Examples of suitable alkanesulphonyl chlorides which may be employed include C2 to C7 alkanesulphonyl chlorides Examples of arenesulphonyl chlorides which may be employed include substituted and unsubstituted benzenesulphonyl chlorides, such as C-, 4 alkoxy, halo, particularly fluoro, chloro and bromo, and C-, 4 alkyl, substituted benzenesulphonyl chlorides When substituted, from 1 to 3 substituents are often present, particularly in the case of alkyl and halo substituents
Examples of suitable alkyl chloroformates which may be employed include C2 to C7 alkyl chloroformates Examples of aryl chloroformates which may be employed include substituted and unsubstituted phenyl chloroformates, such as C, 4 alkoxy, halo, particularly fluoro, chloro and bromo, and C1 4 alkyl, substituted phenyl chloroformates When substituted, from 1 to 3 substituents are often present, particularly in the case of alkyl and halo substituents Examples of suitable alkyl chlorosulphites which may be employed include C2 to
C7 alkyl chlorosulphites Examples of aryl chlorosulphites which may be employed include substituted and unsubstituted phenyl chlorosulphites, such as C1 4 alkoxy, halo, particularly fluoro, chloro and bromo, and C1 4 alkyl, substituted phenyl chlorosulphites When substituted, from 1 to 3 substituents are often present, particularly in the case of alkyl and halo substituents
Examples of suitable alkyl phosphorochloπdates which may be employed include dι(C, to C6 alkyl) phosphorochloπdates Examples of aryl phosphorochloπdates which may be employed include substituted and unsubstituted diphenyl phosphorochloπdates, such as C, 4 alkoxy, halo, particularly fluoro, chloro and bromo, and C, 4 alkyl, substituted diphenyl phosphorochloπdates When substituted, from 1 to 5 substituents on each phenyl group may be present, particularly in the case of alkyl and halo substituents
Further coupling agents that may be employed are the chloro-, bromo- and (benzotπazo-1-yloxy)- phosphonium and carbonium compounds disclosed by Wada et al, in J A C S 1997, 119, pp 12710-12721 (incorporated herein by reference) Examples of suitable carbodnmides that may be employed include alkyl carbodiimides, especially (C, to C6 alkyl) carbodiimides, such as 1 ,3 dicyclohexyl carbodiimide, 1 ,3 dnsopropyl carbodiimide, 1-tert -butyl-3-ethyl carbodnmide and 1-(3- dιmethylamιnopropyl)-3-ethyl carbodiimide One or more of the alkyl groups may be substituted, for example by an alkyl ammo moiety An example of a substituted alkyl carbodiimide is 1-(3-dιmethylamιnopropyl)-3-ethyl carbodiimide
Preferred coupling agents are diaryl phosphorochloridat.es, particularly those having the formula (ArO)2POCI wherein Ar is preferably phenyl, 2-chlorophenyl, 2,4,6- tπchlorophenyl or 2,4,6-trιbromophenyl
The sulphur transfer agents employed in the process of the present invention introduce a protected thio moiety into the linkage, thereby forming a phosphorothioate tnester The phosphorthioate tπesters are commonly subsequently converted to phosphodiester or phosphorothioate diesters, and the sulphur transfer agent can be selected accordingly For example the nature of the sulphur-transfer agent will depend on whether an ohgonucleotide, a phosphorothioate analogue or a mixed ohgonucleotide/ohgonucleotide phosphorothioate is required Sulphur transfer agents employed in the process of the present invention often have the general chemical formula
L s D wherein L represents a leaving group, and D represents an aryl group, a methyl or a substituted alkyl group or an alkenyl group Commonly the leaving group is selected so as to comprise a nitrogen-sulphur bond Examples of suitable leaving groups include morphohnes such as morphohne-3,5-dιone, imides such as phthahmides, succinimides and maleimides, indazoles, particularly indazoles with electron-withdrawing substituents such as 4-nιtroιndazoles, and tπazoles
Where a standard phosphodiester linkage is required in the final product, the sulphur transfer agent is commonly selected such that the moiety D represents an aryl group, such as a phenyl or naphthyl group Examples of suitable aryl groups include substituted and unsubstituted phenyl groups, particularly halophenyl and alkylphenyl groups, especially 4-halophenyl and 4-alkylphenyl, commonly 4-(Cτ 4 alkyl)phenyl groups, most preferably 4-chlorophenyl and p-tolyl groups An example of a suitable class of standard phosphodiester-directing sulphur-transfer agent is an N- (arylsulphanyl)phthahmιde (succinimide or other imide may also be used)
Where a phosphorothioate diester linkage is required in the final product, the moiety D commonly represents a methyl, substituted alkyl or alkenyl group Examples of suitable substituted alkyl groups include substituted methyl groups, particularly benzyl and substituted benzyl groups, such as alkyl-, commonly C, 4alkyl- and halo-, commonly chloro-, substituted benzyl groups, and substituted ethyl groups, especially ethyl groups substituted at the 2-posιtιon with an electron-withdrawing substituent such as 2-(4- nιtrophenyl)ethyl and 2-cyanoethyl groups Examples of suitable alkenyl groups are ally], propargyl and crotyl Examples of a suitable class of phosphorothioate-directing sulphur- transfer agents are, for example, (2-cyanoethyl)sulphanyl derivatives such as 4-[(2- cyanoethyl)-sulphanyl]morphohne-3,5-dιone or a corresponding reagent such as 3-
(phthahmιdosulphanyl)propanonιtrιle
A suitable temperature for carrying out the coupling reaction and sulphur transfer is in the range of from approximately -55°C to about 40°C, such as from 0 to 30°C, and preferably about room temperature (commonly in the range of from 10 to 25°C, for example approximately 20°C)
The coupling and sulphur transfer steps of the process according to the present invention are carried out as often as is necessary to synthesise the desired number of phosphorothioate linkages
Preferred nucleoside or nucleotide H-phosphonates employed in the process of the present invention have the general chemical formula
Figure imgf000009_0001
wherein each B independently is an organic base, each Q independently is H, CH2R' or OR' wherein R' is alkyl, substituted alkyl, alkenyl or a protecting group, each R independently is an aryl, methyl, substituted alkyl or alkenyl group,
W is H, a protecting group or an H-phosphonate group of formula
O
-H
°θM+ in which M+ is a monovalent cation, each X independently represent O or S, each Y independently represents O or S, Z is H, a protecting group or an H-phosphonate group of formula
O
— H
°©M+ in which M+ is a monovalent cation, and n is zero or a positive integer, provided that when W is H or a protecting group, that Z is an H-phosphonate group, and that when Z is H or a protecting group, that W is an H-phosphonate group
Preferably, only one of W or Z is an H-phosphonate group, commonly only Z being an H-phosphonate group
When W or Z represents a protecting group, the protecting group may be one of those disclosed above for protecting the 3' or 5' positions respectively When W is a protecting group, the protecting group is preferably a trityl group, particularly a dimethoxytπtyl group When Z is a protecting group, the protecting group is preferably a trityl group, particularly a dimethoxytntyl group, or an acyl group, preferably a levuhnoyl group
Organic bases which may be represented by B include nucleobases, such as natural and unnatural nucleobases, and especially puπnes, such as hypoxanthine, and particularly A and G, and pynmidines, particularly T, C and U The bases may be protected, with A, G and C preferably being protected Suitable protecting groups include those described hereinabove for the protection of bases
When Q represents a group of OR', and R' is alkenyl, the alkenyl group is often a C, 4 alkenyl group, especially allyl, propargyl or crotyl group When R' represents alkyl, the alkyl is preferably a C1 4 alkyl group When R' represents substituted alkyl, the substituted alkyl group includes alkoxyalkyl groups, especially C-, 4 alkyoxy^ 4 alkyl groups such as methoxyethyl groups When R' represents a protecting group, the protecting group is commonly an acid-labile acetal protecting group, particularly 1-(2- fluorophenyl)-4-methoxypιperιdιne-4-yl (Fpmp) or a tπalkylsilyl groups, often a tπ^ 4- alkyl)sιlyl group such as a tertiary butyl dimethylsilyl group Preferably, X represents O In many embodiments, Y represents S and each R independently represents methyl, substituted alkyl, alkenyl or aryl Preferably, each R independently represents a methyl group, a substituted methyl group, particularly a benzyl or substituted benzyl group, such as an alkyl-, commonly C1 4alkyl- or halo-, commonly chloro-, substituted benzyl group, a substituted ethyl group, especially an ethyl group substituted at the 2- position with an electron-withdrawing substituent such as a 2-(4-nιtrophenyl)ethyl or a 2- cyanoethyl group, a C1 4 alkenyl group, preferably an allyl and crotyl group, or a substituted or unsubstituted phenyl group, particularly a halophenyl or alkylphenyl group, especially 4-halophenyl group or a 4-alkylphenyl, commonly a 4-(C, 4 alkyl)phenyl group, and most preferably a 4-chlorophenyl or a p-tolyl group M+ preferably represents a tπalkyl ammonium ion, such as a trι(C1 4- alkylammonium) ion, and preferably a tπethylammonium ion or a cation of a cyclic base such as 1 ,5-dιazabιcylo[4 3 0]non-5-ene (DBN) or 1 ,8-dιazabιcyclo[5 4 0]undec-7-ene (DBU) n may be 0 or 1 up to any number convenient for the synthesis of the desired ohgonucleotide, particularly up to about 20 Preferably n is 0 to 9, and especially 0 to 7
H-phosphonates wherein n represents 1 , 2 or 3 can be employed when it is desired to add small blocks of nucleotide, with correspondingly larger values of n, for example 4, 5, or 6, being employed if larger blocks of ohgonucleotide are desired to be coupled
The H-phosphonates, coupling agents and sulphur transfer agents can employed as a solution, although the coupling agent or sulphur transfer agent may employed as a neat liquid or solid as appropriate Organic solvents which can be employed include haloalkanes, particularly dichloromethane, esters, particularly alkyl esters such as ethyl acetate, and methyl or ethyl propionate, nitriles, such as acetonitπle, amides, such as dimethylformamide and N-methylpyrolhdinone, and basic, nucleophihc solvents such as pyπdine Preferred solvents are pyπdine, dichloromethane, dimethylformamide, N- methylpyrolhdinone and mixtures thereof
Protecting groups can be removed using methods known in the art for the particular protecting group and function For example, transient protecting groups, particularly gamma keto acids such as levuhnoyl-type protecting groups, can be removed by treatment with hydrazine, for example, buffered hydrazine, such as the treatment with hydrazine under very mild conditions disclosed by van Boom J H , Burgers, P M J Tetrahedron Lett , 1976, 4875-4878 The resulting partially-protected ohgonucleotides with free 3'-hydroxy functions may then be converted into the corresponding H- phosphonates which are intermediates which can be employed for the block synthesis of ohgonucleotides and their phosphorothioate analogues
When deprotecting the desired product once this has been produced, protecting groups on the phosphorus which produce phosphorothioate tnester linkages are commonly removed first For example, a cyanoethyl group can be removed by treatment with anhydrous, strongly basic amine such as DABCO, 1 ,5-dιazabιcylo[4 3 0]non-5-ene (DBN), 1 ,8-dιazabιcyclo[5 4 0]undec-7-ene (DBU) or tnethylamine
Phenyl and substituted phenyl groups on the phosphorothioate intemucleotide linkages and on the base residues can be removed by oximate treatment, for example with the conjugate base of an aldoxime, preferably that of E-2-nιtrobenzaldoxιme or pyπdιne-2-carboxaldoxιme (Reese et al, Nucleic Acids Res 1981 ) Kamimura, T et al in
J Am Chem Soc , 1984, 106 4552-4557 and Sekine, M Et al, Tetrahedron, 1985, 41 , 5279-5288 in an approach to ohgonucleotide synthesis by the phosphotriester approach in solution, based on S-phenyl phosphorothioate intermediates, and van Boom and his co-workers in an approach to ohgonucleotide synthesis, based on S-(4-methylphenyl) phosphorothioate intermediates (Wreesman, C T J et al, Tetrahedron Lett , 1985, 26,
933-936) have all demonstrated that unblocking S-phenylphosphorothioates with oximate ions (using the method of Reese et al , 1978, Reese, C B,, Zard, L Nucleic Acids Res , 1981 , 9, 4611-4626) led to natural phosphodiester intemucleotide linkages In the present invention, the unblocking of S-(4-chlorophenyl)-protected phosphorothioates with the conjugate base of E-2-nιtrobenzaldoxιme proceeds smoothly and with no detectable intemucleotide cleavage
Other protecting groups, for example benzoyl, pivaloyl and amidine groups can be removed by treatment with concentrated aqueous ammonia
Trityl groups present can be removed by treatment with acid With regard to the overall unblocking strategy in ohgonucleotide synthesis, another important consideration of the present invention, is that the removal of trityl, often a 5'-termιnal DMTr, protecting group ('detπtylation') should proceed without concomitant depuπnation, especially of any 6-Λ/-acyl-2'-deoxyadenosιne residues Silyl protecting groups may be removed by fluoride treatment, for example with a solution of an ammonium fluoride, for example a solution of tπalkylamine tπhydrogen fluoride or a solution of a tetraalkyl ammonium fluoride salt such as tetrabutyl ammonium fluoride
Fpmp protecting groups may be removed by acidic hydrolysis under mild conditions
This new approach to the synthesis of ohgonucleotides is suitable for the preparation of sequences with (a) solely phosphodiester, (b) solely phosphorothioate diester and (c) a combination of both phosphodiester and phosphorothioate diester intemucleotide linkages Solid supports that are employed in the process according to the present invention are substantially insoluble in the solvent employed, and include those supports well known in the art for the solid phase synthesis of ohgonucleotides Examples include silica, controlled pore glass, polystyrene, copolymers comprising polystyrene such as polystyrene-poly(ethylene glycol) copolymers and polymers such as polyvinylacetate Additionally, poly(acrylamιde) supports, especially microporous or soft gel supports, such as those more commonly employed for the solid phase synthesis of peptides may be employed if desired Preferred poly(acrylamιde) supports are amine-functionahsed supports, especially those derived from supports prepared by copolymeπsation of acryloyl-sarcosine methyl ester, N,N-dιmethylacrylamιde and bis-acryloylethylenediamine, such as the commercially available (Polymer Laboratories) support sold under the catalogue name PL-DMA The procedure for preparation of the supports has been described by Atherton, E , Sheppard, R C , in Solid Phase Synthesis A Practical Approach, Publ , IRL Press at Oxford University Press (1984) The functional group on such supports is a methyl ester and this is initially converted to a primary amine functionality by reaction with an alkyl diamine, such as ethylene diamine
The substrate is commonly bound to the solid support via a cleavable linker Examples of linkers that may be employed include those well known in the art for the solid phase synthesis of ohgonucleotides, such as urethane, oxalyl, succinyl, and amino- deπved linkers In many embodiments when the substrate is bound to a poly(acrylamιde) support via a cleavable linker and comprises a nucleoside, the substrate is attached to the support by a process comprising either a) reacting a 5'-protected nuceloside having a free 3'-hydroxy group with a linker, preferably succinic anhydride, to form a linker-deπvatised nucleoside, and b) reacting the linker-deπvatised nucleoside with an amine-functionahsed poly(acrylamιde) support in the presence of a coupling agent used for amide bond formation and optionally a catalyst, such as a base, for example dnsopropylethylamine (DIPEA) or N-methylmorphohne (NMM), or hydroxybenzotπazole, or c) reacting an amine-functionahsed poly(acrylamιde) support with a linker, preferably succinic anhydride, to form a hnker-denvatised support, and d) reacting the hnker-denvatised support with a 5'-protected nuceloside having a free 3'- hydroxy group in the presence of a coupling agent used for amide bond formation and optionally a catalyst, such as a base, for example DIPEA or NMM, or hydroxybenzotπazole, then in either case, removing the 5'-protectιng group, which is preferably a trityl or substituted trityl group However, it will be recognised that it may be desired to retain the 5'-protectιng group in which case its removal may be omitted In this case, the 5'- protecting group can be removed when desired prior to use of the supported substrate in the process for the synthesis of phosphorothioate tπesters according to the present invention
Coupling agents used for amide bond formation that can be employed in the process for attaching the substrate to an amine-functionahsed poly(acrylamιde) support include those known in the art of peptide synthesis, see for example those coupling reagents disclosed by Wel ngs, D A , Atherton, E , in Methods in Enzymology, Publ , Academic Press, New York (1997) incorporated herein by reference, such as those comprising carbodiimides, especially dialkyl carbodiimides such as N,N'- diisopropylcarbodnmide (DIC) and reagents that form active esters particularly benzotπazole active esters in situ, such as 2-(1 H-benzotπazole-1-yl)-1 , 1 ,3,3- tetramethyluronium tetrafluoroborate (TBTU) or benzotπazole-1-yloxy-tπs-
(dιmethylamιno)phosphonιum hexafluorophosphate (BOP)
An organic solvent such as N,N-dιmethylformamιde (DMF) or N- methylpyrrohdinone (NMP) is suitably employed for attaching the substrate to an amine- functiona sed poly(acrylamιde) support The process for the synthesis of phosphorothioate tπesters according to the present invention can be carried out by stirring a slurry of the substrate bonded to the solid in a solution of the H-phosphonate and coupling agent or sulphur-transfer agent Alternatively the solid support can be packed into a column, and solutions of H- phosphonate and coupling agent, followed by sulphur transfer agent can be passed sequentially through the column
The process according to the present invention is preferably employed to produce ohgonucleotides typically comprising 3 or more bases The upper limit will depend on the length of the ohgonucleotide it is desired to prepare Often, ohgonucleotides produced by the process of the present invention comprise up to 40 bases, commonly up to 30 bases and preferably from 5 to 25, such as from 8 to 20, bases The coupling and sulphur transfer steps of the process of the present invention are repeated sufficient times to produce the desired length and sequence
On completion of the assembly of the desired product, the product may be cleaved from the solid support, preferably following deprotection of the product When the desired product is an ohgonucleotide, it will be recognised that the product will be a phosphate diester, phosphorothioate diester or chimera comprising both phosphate diester and phosphorothioate diester moieties Cleavage methods employed are those known in the art for the given solid support When the product is bound to the solid support via a cleavable linker, cleavage methods appropriate for the linker are employed Following cleavage, the product can be purified using techniques known in the art, such as one or more of ion-exchange chromatography, reverse phase chromatography, and precipitation from an appropriate solvent Further processing of the product by for example ultrafiltration may also be employed The invention will now be illustrated without limitation by the following examples
Example 1
4-Λ/-benzoyl-5'-0-(4,4'-dιmethoxytrιtyl)-2'-deoxycytιdιne (DMT C z) supported via a succinimide linker at the 3'-posιtιon to a polystyrene support (commercially available under the trade name Pharmacia Primer Support 30HL, loading 84 umol/g, 2g) was poured into a sintered vessel, wetted with 100ml of CH2CH2, and aerated with house nitrogen The solvent was removed Following this wash procedure, the supported DMT Cbz was treated as follows i) with 100ml of 3% v/v dichloroacetic acid in dichloromethane (DCA/DCM) - Wait for 60 seconds, remove DCA/DCM n) with 100ml of CH2CH2 - Wait for 60 seconds, remove CH2CH2 in) with 100ml of 3% DCA/DCM - Wait for 60 seconds, remove acid iv) Wash with 100ml CH2CH2 - Wait for 60 seconds, and finally v) Wash with more CH2CH2 (100ml) and dry resin with N2 to produce supported 4-Λ/-benzoyl-2'-deoxycytιdιne (HOCbz-poly)
Quantities Equivs Amount
822 DMTAbz (H) 5 0 0 84mmol - 690mg
HOCbz-poly 1 0 0 168mmol
232 CESP 10 0 1 68mmol - 389mg 268 5/1/3 Activator* 10 0 1 68mmol - 0 35ml
* As a 1 1 solution in DCM use 0 69ml 6-Λ/-benzoyl-5'-O-(4,4'-dιmethoxytrιtyl)-2'-deoxyadenosιne-3'-H-phosphonate (DMTAbz(H), 690mg) was dried by co-evaporation (2x5ml) with anhydrous pyndine, and combined with 2g of HOCbz-poly (in a 100ml florentine) Pyndine was added such that all the DMTAbz(H) was in solution and a heterogeneous slurry was formed This required 40ml of pyndine The mixture was cooled to -40°C and this was maintained during both coupling and sulphur transfer stages The reaction mixture was purged with argon, and the reaction was carried out under a blanket of this gas 0 35ml (0 69ml of 1 1 vol/vol mixture in anhydrous dichloromethane) of diphenylphosphorochloπdate was added drop- wise over 5 minutes to the cooled, stirred slurry and left stirring for a further 15 minutes At this point 389mg 2-(2-cyanoethyl)sulphanyl phthahmide (CESP) in 8ml of pyndine was added in one aliquot The mixture was initially stirred at -40°C and then allowed to warm to room temperature The slurry was then transferred to a sinter, washed with pyndine (50ml) and DCM (200ml) and the resin dried under vacuum to produce 5'-(DMT)-Abz-O- P(=O)(SCH2CH2CN)-Cbz-(3'-O-polymer support) ("DMT-AC-poly")
DMT-AC-poly (1 4g@71 μmolg 1 loading) was treated for 60 seconds at room temperature with 200ml of a 3% solution of dichloroacetic acid in CH2CH2 The resin was washed with clean CH2CH2 and dried in a stream of N2 to produce 5'-(HO)-A z-O- P(=O)(SCH2CH2CN)-Cbz-(3'-O-polymer support) ("HO-AC-poly")
Equivs Amount
2235 DMTACAC(H) 5 0 0 46mmol - 1 03g
71 μmol/g HO-AC-poly 1 0 13g@ 71 μmol/g
232 CESP 10 0 0 923mmol - 214mg
268 5/13 Activator 10 0 *0 923mmol - 0 19ml
Figure imgf000015_0001
A 5'-DMT protected nucleotide 3'-H-phosphonate having the base sequence 5'- DMT-ACAC, with each intemucleotide being protected by a beta-cyanoethylthio moiety (5'-DMT-ACAC-3'-H phosphonate) was prepared from the corresponding tetrameπc ohgonucleotide comprising a free 3'-hydroxy group (5'-DMT-ACAC-3'-OH) as follows Ammonium toluyl-H-phosphonate was dissolved in 50ml methanol and 5ml tπethylamine This mixture is evaporated to form a gum, and the gum redissolved in 100ml pyndine, together with 12 3g 5'-DMT-ACAC-3'-OH, and the pyndine evaporated The residue was then redissolved in 50ml pyndine The pyndine solution is cooled to -30°C and pivaloyl chloride (2 2ml) added over 1 minute The mixture was stirred for 30 minutes, and 15ml water is added After 10 minutes stirring, 250ml of a solution of 10% v/v methanol in dichloromethane was added, and this was washed with 0 5M tπethylammonium phosphate buffer The organic layer was separated, diluted with 25ml methanol and the wash repeated The organic layer was separated, evaporated from 100ml toluene, and then evaporated from 200ml 50 50 by vol toluene/pyπdine mixture The crude gum is redissolved in dichloromethane, and purified by column chromatography to yield 5'-DMT- ACAC-3'-H phosphonate The 5'-DMT-ACAC-3'-H phosphonate was dried by co-evaporation from anhydrous pyndine (2x5ml) and re-suspended in 40ml of the same solvent The mixture was combined with 1 3g of HO-AC-poly in a 100ml florentine The heterogeneous mixture was stirred, blanketed in Argon and cooled to -40°C 0 38ml of 1 1 vol/vol diphenylphosphorochloπdate in CH2CH2 was added drop-wise over 5 minutes, and the mixture stirred for a further 15 minutes At this point CESP (214mg in 5ml pyndine) was added in one aliquot The mixture was initially stirred at -40°C and then allowed to warm to room temperature over 20 minutes prior to quench (1 ml of water)
The slurry was transferred to a sinter, and was filtered and washed (5x100ml of CH2CH2) and dried over nitrogen to produce 5'-(DMT) -Abz-O-P(=O)(SCH2CH2CN)-Cbz-O- P(=O)(SCH2CH2CN) -Abz-O-P(=O)(SCH2CH2CN)-Cbz-O-P(=O)(SCH2CH2CN)-Abz-O-
P(=O)(SCH2CH2CN)-Cbz- (3'-O-polymer support) ("DMT-ACACAC-poly")
The cyanoethyl groups can be removed by treatment with anhydrous 1 ,8- dιazabιcyclo[5,4,0]undec-7-ene to yield phosphorothioate linkages, and the phosphorothioate ohgonucleotide could be cleaved from the support by treatment with concentrated aqueous ammonia containing 10% vol mercaptoethanol
Example 2. General Methodology for H-Phosphonate Coupling and Sulfur Transfer on Poly(dimethylacrylamide) (PDMA)
A poly(acrylamιde) resin produced by copolymeπsation of acryloyl-sarcosine methyl ester, N,N-dιmethylacrylamιde and bis-acryloylethylenediamine (PDMA resin, 69g) was treated with ethylene diamine (700ml) in a 2L round bottomed flask which was sealed and allowed to stand at room temperature overnight The slurry was then transferred to a sinter funnel and washed with DMF (12x 700ml) This produced DMF washings containing no trace of amine The resin was then washed with DMF containing an increasing gradient of DCM (2 5L, 0-100% DCM) then an increasing gradient of ether in DCM (900ml, 0-100% ether) The resin was then dried overnight in a stream of nitrogen at 40°C The resin produced had an ammo functionahsation of 973 micromoles per gram ("Ammo-PDMA resin") A solution of 4-Λ/-benzoyl-5'-0-(4,4'-dιmethoxytrιtyl)-2'-deoxycytιdιne-3'-O- succmate ("DMT-Cbz-succιnate", 3eqvs, 234 mmol), hydroxybenzotπazole (6 eqvs, 467 mmol) and DIC (diisopropyl carbodiimide, 4 eqvs, 31 mmol) was prepared in 1300ml of DMF The solution was prepared in a 2L flask which had previously been silanised (this was achieved by simply swirling tπmethylsilyl chloride around the flask) in order to prevent the resin from adhering to glass The Amino-PDMA resin (1 eqv, 78 mmol) was then added to the solution and left to stand overnight at room temperature This resulted in a stiff non-mobile gel After 22 hrs a few beads were removed and washed with fresh DMF The resin was found to be Kaiser negative, indicating that all the ammo groups on the resin had reacted with DMT-Cbz-succιnate The reaction mixture was then transferred to a sintered funnel (18cm diameter, porosity 3) and washed (5 x 800ml) After the final DMF wash a similar diethyl ether treatment as described for the ammo PDMA was carried out in order to shrink the resin After blowing dry with N2 for 24 hours and then drying in the vacuum oven overnight the resin was weighed This gave a weight increase of 55 7g from the original 80g of Amino-PDMA This resulted in DMT-Cbz-PDMA resin loaded to 573 mmol per gramme
A 5'-DMT-deoxycytιdιne dimer (protected on the mternucleoside phsophorus by a β-cyanoethyl group) was also attached to the resin at a similar loading using identical conditions to above The loaded resin was prepared for coupling by having the DMT group removed as follows DMT-Cbz-PDMA resin is poured into a sintered funnel (7cm, porosity 3) and a positive pressure of nitrogen is applied A 3% solution of DCA in DCM (15ml/g resin) is then added to the resin and left to bubble gently for 5 minutes This was repeated (twice, quantities same as above) All of the orange colour was removed from the resin at this point indicating that detπtylation is complete Residual acid was removed by washing with
DCM and further washing carried out with ether in DCM, starting at 20%v/v ether and continuing to 100% ether The HO-Cbz-PDMA resin is then air dried and dried m-vacuo at 40°C overnight
HO-Cbz-PDMA resin (1 mmol, 1 48g), DMT-Cbz-H-phosphonate (6 eq, 4 79g) were weighed into a 100ml florentme This was then suspended in 60ml of anhydrous grade
DMF The mixture was left for 5 minutes to allow the resin to swell to its maximum capacity at room temperature and pyndine (4 36ml) was added The reaction mixture was then stirred using a small (12x5mm) flea (at maximum stir rate on a Heidolph MR3001 K stirrer hotplate) The neat activator, diphenyl phosphorochloπdate (6 eq 1 24ml) was added dropwise, during a 5 minute period, using the syringe pump (Razel
A99FZ) Immediately after the addition was complete, the sulfur transfer reagent (CESP 232mg, 1 mmol), was added to the mixture as a solid single aliquot After 5 minutes more the resin mixture was poured into a sintered funnel (porosity 3) The resin was then washed for 5 minutes, with stirring, using 50ml of DMF This process was repeated a further two times At this point any un-reacted hydroxyl groups were capped by treatment with 35ml of a 1 4M solution of acetic anhydride in pyndine containing 4-(N,N- dιmethyl)amιnopyrιdιne (DMAP, 0 5mmol) for 20 mins, followed by further washing with DMF ( 3x 30ml) At the end of the final wash as much DMF as possible was removed prior to washing the resin with 100ml of diethyl ether The resin was stirred during the ether addition and the solvent allowed to drop through the sinter under gravity The ether wash was repeated twice more After the final wash the remaining ether was removed by passing N2 through the resin for 30 minutes The resin was then dried overnight in vacuo at 40°C The weight increase of the resin and trityl assay indicated quantitative coupling to form DMT-CbzCbz-PDMA, protected on the internucleoside linkage with a β-cyanoethyl group
Preparation of 5'-HO-A zCbzAbzCbzCbz-PDMA
HO-Cbz-PDMA resin prepared as above (1 mmol, 1 48g) and 5'-DMT-AbzCbzAbzC z- H-phosphonate protected on the internucleoside linkages with β-cyanoethyl groups ( 1 2eq, 2 68g) were weighed into a 100ml florentme Anhydrous DMF (60ml) was added and the resin allowed to swell for 5 mms at room temperature Pyndine (5mmol, 0 4ml) was added followed by the coupling agent, diphenyl phosphorochloπdite (2mmol, 0 41 ml) which was added dropwise during 5 mms using a syringe pump as above On completion of this addition, sulfur transfer agent (CESP, 2 5mmol, 0 58g) was added solid as a single aliquot and the suspension stirred for one hour The solid was then washed with DMF followed by DCM and the DMT group removed by treatment with dichloroacetic acid as above The resin was then washed with DCM, DMF and finally ether before being dried in a stream of nitrogen and then in vacuo at 40°C overnight The weight increase and a trityl assay indicated a yield of 75%

Claims

1 A process for the synthesis of a phosphorothioate tnester comprising the reaction, in the presence of a coupling agent, of an H-phosphonate with a substrate comprising a free hydroxy group and bonded to a solid support, thereby forming a supported H- phosphonate diester, and subjecting the H-phosphonate diester to sulphur transfer with a sulphur transfer agent thereby forming a phosphorothioate tnester
2 A process according to claim 1 , wherein a plurality of coupling and sulphur transfer steps are carried out, with a sulphur transfer step being carried out after each coupling step
3 A process according to claim 1 or claim 2, wherein the H-phosphonate is a 2'- deoxyπbonucleoside, ribonucleoside, ohgodeoxyribonucleotide or oligonbonucleotide
4 A process according to claim 3, wherein the 2'-deoxyπbonucleosιde, ribonucleoside, ohgodeoxyribonucleotide or oligonbonucleotide comprises a 3' H- phosphonate function
5 A process according to any preceding claim, wherein the substrate comprising a free hydroxy group is a deoxynbonucleoside, ribonucleoside, ohgodeoxyribonucleotide or oligonbonucleotide
6 A process according to claim 5, wherein the substrate comprising a free hydroxy group is a deoxynbonucleoside, ribonucleoside, ohgodeoxyribonucleotide or oligonbonucleotide derivative comprising a free 5'-hydroxy group and is bonded to the solid support via the 3'-posιtιon
7 A process according to any preceding claim, wherein the coupling agent is an alkyl phosphorochloπdate or an aryl phosphorochloπdates, and preferably diphenyl phosphorochloπdate
8 A process according to any preceding claim, wherein the sulphur transfer agent has the general chemical formula
L s D
wherein L represents a leaving group, and D represents an aryl group, a methyl or a substituted alkyl group or an alkenyl group 9 A process according to any preceding claim wherein the reaction between the H- phosphonate and the substrate comprising a free hydroxy group and the reaction between the H-phosphonate diester and the sulphur transfer agent takes place in the presence of an organic solvent selected from the group consisting of haloalkanes, esters, nitnles, amides and basic, nucleophihc solvents, and mixtures thereof
10 A process according to claim 9, wherein the organic solvent is selected from the group consisting of pyndine, dichloromethane, dimethylformamide, N-methylpyrolhdinone and mixtures thereof
11 A process according to any preceding claim, wherein the solid support is selected from the group consisting of silica, controlled pore glass, polystyrene, copolymers comprising polystyrene, polyvinylacetate and poly(acrylamιde) supports
12 A process according to claim 11 , wherein the solid support is an amine- functiona sed support copolymer of acryloyl-sarcosine methyl ester, N,N- dimethylacrylamide and bis-acryloylethylenediamine
13 A process according to any preceding claim, wherein the process is carried out at a temperature in the range of from approximately -55°C to about 40°C, and preferably from 0 to 30°C
14 A process according to any preceding claim, wherein hydroxy groups which are unreacted after a given coupling are capped by reaction with a capping agent
15 A process according to any preceding claim wherein the phosphorothioate tnester is an ohgonucleotide, and the process comprises the additional steps of deprotectmg the phosphorothioate tnester, and cleaving the product thereof from the solid support thereby to form a phosphate diester, phosphorothioate diester or chimera comprising both phosphate diester and phosphorothioate diester moieties, optionally followed by one or more purification processes
PCT/GB2000/003912 1999-10-14 2000-10-12 Process for the preparation of phosphorothioate triesters and oligonucleotides WO2001027126A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU78035/00A AU7803500A (en) 1999-10-14 2000-10-12 Process for the preparation of phosphorothioate triesters and oligonucleotides
EP00968075A EP1224193A1 (en) 1999-10-14 2000-10-12 Process for the preparation of phosphorothioate triesters and oligonucleotides
JP2001530344A JP2003517467A (en) 1999-10-14 2000-10-12 Method for preparing phosphothioate triester and oligonucleotide
CA002386867A CA2386867A1 (en) 1999-10-14 2000-10-12 Process for the preparation of phosphorothioate triesters and oligonucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9924285.1 1999-10-14
GBGB9924285.1A GB9924285D0 (en) 1999-10-14 1999-10-14 Process

Publications (1)

Publication Number Publication Date
WO2001027126A1 true WO2001027126A1 (en) 2001-04-19

Family

ID=10862710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003912 WO2001027126A1 (en) 1999-10-14 2000-10-12 Process for the preparation of phosphorothioate triesters and oligonucleotides

Country Status (7)

Country Link
EP (1) EP1224193A1 (en)
JP (1) JP2003517467A (en)
CN (1) CN1409719A (en)
AU (1) AU7803500A (en)
CA (1) CA2386867A1 (en)
GB (1) GB9924285D0 (en)
WO (1) WO2001027126A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064702A1 (en) * 2000-03-01 2001-09-07 Avecia Limited Process for the preparation of phosphorothioate triesters
JP2006512336A (en) * 2002-12-18 2006-04-13 アベシア・リミテッド Method for purifying oligonucleotide synthons
US7227017B2 (en) * 2000-12-05 2007-06-05 Avecia Limited Process for the preparation of phosphorothioate oligonucleotides
US8569476B2 (en) 2008-09-23 2013-10-29 Suzhou Ribo Life Science Co., Ltd. Method for preparing oligonucleotide
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
WO2015107425A2 (en) 2014-01-16 2015-07-23 Wave Life Sciences Pte. Ltd. Chiral design
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
US9617547B2 (en) 2012-07-13 2017-04-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739899A2 (en) * 1988-04-27 1996-10-30 Isis Pharmaceuticals, Inc. Novel oligoribonucleotide derivatives and application thereof to antiviral agents
WO1999009041A2 (en) * 1997-08-13 1999-02-25 Avecia Limited Solution phase synthesis of oligonucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739899A2 (en) * 1988-04-27 1996-10-30 Isis Pharmaceuticals, Inc. Novel oligoribonucleotide derivatives and application thereof to antiviral agents
WO1999009041A2 (en) * 1997-08-13 1999-02-25 Avecia Limited Solution phase synthesis of oligonucleotides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRILL W K -D: "Thioalkylation of Nucleoside-H-phosphonates and its Application to Solid Phase Synthesis of Oligonucleotides", TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 36, no. 5, 30 January 1995 (1995-01-30), pages 703 - 706, XP004028873, ISSN: 0040-4039 *
KLOSE J ET AL: "Preparation of 2-(2-Cyanoethyl)sulfanyl-1H-isoindole-1,3-(2H)-dione and Related Sulfur-Transfer Agents", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 53, no. 42, 20 October 1997 (1997-10-20), pages 14411 - 14416, XP004106325, ISSN: 0040-4020 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064702A1 (en) * 2000-03-01 2001-09-07 Avecia Limited Process for the preparation of phosphorothioate triesters
US7022833B2 (en) 2000-03-01 2006-04-04 Avecia Limited Process for the preparation of phosphorothioate triesters
US7227017B2 (en) * 2000-12-05 2007-06-05 Avecia Limited Process for the preparation of phosphorothioate oligonucleotides
JP4824931B2 (en) * 2002-12-18 2011-11-30 アベシア・バイオテクノロジー・インコーポレーテッド Method for purifying oligonucleotide synthons
JP2006512336A (en) * 2002-12-18 2006-04-13 アベシア・リミテッド Method for purifying oligonucleotide synthons
US8569476B2 (en) 2008-09-23 2013-10-29 Suzhou Ribo Life Science Co., Ltd. Method for preparing oligonucleotide
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
US10329318B2 (en) 2008-12-02 2019-06-25 Wave Life Sciences Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
US9695211B2 (en) 2008-12-02 2017-07-04 Wave Life Sciences Japan, Inc. Method for the synthesis of phosphorus atom modified nucleic acids
US10307434B2 (en) 2009-07-06 2019-06-04 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
US10280192B2 (en) 2011-07-19 2019-05-07 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
US10167309B2 (en) 2012-07-13 2019-01-01 Wave Life Sciences Ltd. Asymmetric auxiliary group
US9982257B2 (en) 2012-07-13 2018-05-29 Wave Life Sciences Ltd. Chiral control
US9617547B2 (en) 2012-07-13 2017-04-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
US10590413B2 (en) 2012-07-13 2020-03-17 Wave Life Sciences Ltd. Chiral control
EP4219516A2 (en) 2012-07-13 2023-08-02 Wave Life Sciences Ltd. Chiral control
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
WO2015107425A2 (en) 2014-01-16 2015-07-23 Wave Life Sciences Pte. Ltd. Chiral design
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design

Also Published As

Publication number Publication date
CA2386867A1 (en) 2001-04-19
JP2003517467A (en) 2003-05-27
CN1409719A (en) 2003-04-09
EP1224193A1 (en) 2002-07-24
GB9924285D0 (en) 1999-12-15
AU7803500A (en) 2001-04-23

Similar Documents

Publication Publication Date Title
EP1343802B1 (en) Process for the preparation of oligonucleotides
US5252723A (en) Method and reagent for sulfurization of organophosphorous compounds
WO2001027126A1 (en) Process for the preparation of phosphorothioate triesters and oligonucleotides
US20050240015A1 (en) Solution phase synthesis of oligonucleotides
IE74706B1 (en) A method of linking nucleosides with a siloxane bridge
US6768005B2 (en) Process
EP1272501B1 (en) Process for the preparation of phosphorothioate triesters
AU2001235766A1 (en) Process for the preparation of phosphorothioate triesters
US20030229218A1 (en) Synthons for oligonucleotide synthesis
US6531589B1 (en) Base protecting groups and synthons for oligonucleotide synthesis
AU749343C (en) Solution phase synthesis of oligonucleotides
US7741471B2 (en) Reagents for the improved synthesis of isoguanosine containing oligonucleotides
WO2003045969A1 (en) Coupling reagent for h-phosphonate chemistry
MXPA00001408A (en) Solution phase synthesis of oligonucleotides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/00431/MU

Country of ref document: IN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000968075

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00431/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2386867

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 530344

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008169772

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000968075

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642